Early Scientific and Clinical Strategy for Optimizing Value Inflection in Oncology Financing and Dealmaking

1:00 PM - 2:00 PM (PDT), Monday, June 13, 2022 ・ Upper Level, Session Room 6C

Pre-POC biotechs, including platform companies, are increasingly recognizing the importance of early, scientifically grounded but clinically and commercially informed thinking around what targets and/or indications to pursue, often in advance of initial signals in human clinical studies. Such rationally based analyses can provide robust credibility and defensibility not only for internal decision-making but also for external communication to prospective investors and partners. Such early proactive and provisional direction, supported by appropriate objective research outside the echo chamber of the company itself, can substantially strengthen the internal and external story (the “pitch”) and significantly help drive value. The panel of experienced industry executives and board members will share their experiences and lessons learned from the hot seat, and discuss key strategic considerations with potential to drive, or attrit, significant value.


 

Moderator
photo
EVP, Oncology Practice Head
Cello Health BioConsulting
Speakers
photo
Chief Commercial Officer, Immune Medicine
Adaptive Biotechnologies
photo
SVP, Business Development & Corporate Strategy
Harpoon Therapeutics
photo
Chief Medical Officer
Hummingbird Bioscience